Rationale: Despite recent clinical trials demonstrating improved outcome in acute respiratory distress syndrome (ARDS), mortality remains high. Partial liquid ventilation (PLV) using perfluorocarbons has been shown to improve oxygenation and decrease lung injury in various animal models. Objective: To determine if PLV would have an impact on outcome in patients with ARDS. Methods: Patients with ARDS were randomized to (1 ) conventional mechanical ventilation (CMV; n ϭ 107), (2 ) "low-dose" perfluorocarbon (10 ml/kg; n ϭ 99), and (3 ) "high-dose" perfluorocarbon (20 ml/kg; n ϭ 105). Patients in all three groups were ventilated using volume ventilation, Vt р 10 ml/kg predicted body weight, rate р 25/min, inspiratory-to-expiratory ratio р 1:1, FI O 2 у 0.5, and positive end-expiratory pressure у 13 cm H 2 O. Results: The 28-d mortality in the CMV group was 15%, versus 26.3% in the low-dose (p ϭ 0.06) and 19.1% in the high-dose (p ϭ 0.39) PLV groups. There were more ventilator-free days in the CMV group (13.0 Ϯ 9.3) compared with both the low-dose (7.4 Ϯ 8.5; p Ͻ 0.001) and high-dose (9.9 Ϯ 9.1; p ϭ 0.043) groups. There were more pneumothoraces, hypoxic episodes, and hypotensive episodes in the PLV patients. Conclusions: PLV at both high and low doses did not improve outcome in ARDS compared with CMV and cannot be recommended for patients with ARDS.
dependent lung regions, by clearing retained secretions, and by redistributing blood flow to ventilated regions (10, 11) ; and the use of PLV abrogates lung injury due to the low surface tension properties and antiinflammatory properties of PFCs (12, 13) . In animal models of acute lung injury (ALI), PLV has been shown to improve gas exchange and decrease lung injury compared with conventional mechanical ventilation (CMV) (14) (15) (16) . Preliminary studies have demonstrated that PLV can be performed safely in humans (17) (18) (19) (20) (21) and a post hoc analysis of a phase II trial demonstrated more rapid discontinuation of mechanical ventilation and a trend to decreased mortality in patients younger than 55 yr who were treated with PLV (20) .
On the basis of the strong animal data (14) (15) (16) suggesting the efficacy of PLV in models of lung injury, and on the suggestive human data (20) , we performed a randomized clinical trial comparing PLV with CMV in patients with ARDS.
METHODS
Between 1998 and 2000, patients with ARDS were randomized from 56 centers (Appendix 1). Inclusion criteria were as follows: risk factor for ALI/ARDS; prior mechanical ventilation for 120 h or less; acute, bilateral infiltrates on chest radiograph; and a Pa O 2 /Fi O 2 of 200 mm Hg or less with an Fi O 2 of 0.5 or greater, and positive end-expiratory pressure (PEEP) of 5 cm H 2 O or more. Patients were excluded if their age was younger than 16 or older than 65 yr, their Acute Physiology and Chronic Health Evaluation (APACHE) II score was 30 or more, it had been more than 48 h since meeting inclusion criteria, and there was presence of serious nonpulmonary organ dysfunction (Appendix 2). To ensure persistent hypoxemia, only patients with Pa O 2 /Fi O 2 greater than 70 and less than 300 mm Hg on PEEP of 13 cm H 2 O or greater and Fi O 2 of 0.5 or more were included.
Patients were randomly assigned to one of four groups using a block design (22) that ensured a balance of distribution of patients with respect to four strata (ARDS etiology, age, APACHE II score, and alternative therapies). Group assignment was performed using a computerized randomization system. The control group received CMV with no PFC; the low-dose PLV group had their lungs filled with PFC (Perflubron, Alliance Pharmaceutical, San Diego, CA) to the carina in the supine position. This was accomplished by slowly instilling two separate aliquots (5 ml/kg predicted body weight [PBW] per aliquot) of PFC into the lungs. A "suction catheter check" was performed by inserting a suction catheter to the carina while the patient was on zero PEEP. Suction was then applied to the catheter; if PFC was suctioned, then suctioning was continued until no PFC was removed. If no PFC was suctioned, then 5-ml/kg aliquots of PFC were administered, followed by suction catheter checks until some PFC was suctioned. The protocol for high-dose PLV group was similar to that described above, except dosing was to obtain PFC to a level 5 cm caudal to the incisors. Supplemental dosing was provided every 3 h; a suction catheter fluid level check was performed every 6 h, and dosing adjusted. In the control group, sham suctioning checks (insertion of the catheter) were mandated every 3 h; however, suctioning occurred only if required clinically. The two treatment groups received PLV for a minimum of 48 h. Supplemental dosing was continued for up to another 72 h if the Fi O 2 was greater than 0.5.
All groups received standardized ventilatory support: volume control, Vt of 10 ml/kg PBW or less, rate of 25/min or less, inspiratoryto-expiratory ratio of 1:1, Fi O 2 of 0.5 or greater, and PEEP of 13 cm H 2 O or more. End-inspiratory plateau pressure was maintained at 35 cm H 2 O or lower. PEEP in the treatment groups was maintained at 13 cm H 2 O or higher until dosing was stopped. When patients met target gas exchange criteria with PEEP of 8 cm H 2 O or less, Fi O 2 of 0.5 or less, patients were weaned using spontaneous breathing trials (23, 24 
RESULTS
A total of 3,817 patients were screened between December 1998 and December 2000, from which 311 patients were enrolled: 107 patients were randomized to CMV, 99 were randomized to lowdose PLV, and 105 were randomized to high-dose PLV. Five patients randomized to PLV (two randomized to low-dose and three randomized to high-dose) never received PLV. These five patients were included in all analyses except for ventilator settings at 24, 72, and 168 h postrandomization. All patients were monitored for the 28-d study period.
Baseline demographic characteristics, disease severity, and ventilator management were similar in the three groups ( Table 1) . The duration of PLV treatment was 92 Ϯ 39.2 h in the low-dose group (n ϭ 97) and 85 Ϯ 39.5 h in the high-dose group (n ϭ 102). Nine patients (five in the low-dose and four in the highdose PLV groups) received PLV therapy for more than 5 d. The total volume of Perflubron instilled into the lungs was 82 Ϯ 32.8 ml/kg PBW (5,179 Ϯ 2,150 ml) in the low-dose PLV group and 107 Ϯ 45.8 ml/kg PBW (6,910 Ϯ 3,278 ml) in the high-dose group.
During the study period, prone ventilation was used in five patients randomized to CMV, two patients randomized to lowdose PLV, and four patients randomized to high-dose PLV. In addition, six patients in the CMV group received inhaled nitric oxide; seven in the low-dose PLV group and 10 in the highdose PLV group also received inhaled nitric oxide. Two patients received high-frequency oscillatory ventilation in the low-dose PLV group, and three patients in the high-dose PLV group received unidentified adjunctive therapy.
Efficacy
Ventilatory and gas exchange variables at 24, 72, and 168 h after randomization are provided in Table 2 . At 24 and 72 h, the CMV group had a lower plateau pressure, peak inspiratory pressure, mean airway pressure, respiratory rate, Fi O 2 , total PEEP, and Pa CO 2 (p Ͻ 0.05), and a higher Pa O 2 /Fi O 2 and pH (p Ͻ 0.05) than both PLV groups. Vt was lower (p Ͻ 0.05) in the low-dose PLV group at 24 and 72 h than in the CMV group. At 168 h, the mean airway pressure was higher and the Pa O 2 /Fi O 2 lower in the low-dose group than in the CMV group (p Ͻ 0.05), and the minute ventilation and total PEEP were higher in the high-dose PLV group than in the CMV group (p Ͻ 0.05).
The results for the main outcomes are provided in Table 3 . There were more ventilator-free days in the CMV group (13.0 Ϯ 9.3) compared with both the low-dose PLV group (7.4 Ϯ 8.5; p Ͻ 0.001) and the high-dose PLV group (9.9 Ϯ 9.1; p ϭ 0.043). The number of weaning attempts per day when meeting weaning criteria did not differ among groups (0.7, low-dose PLV; 0.9, high-dose PLV; 0.8, CMV) nor did the number of weaning attempts per day when not meeting weaning criteria (0.3, lowdose PLV; 0.4, high-dose PLV; 0.3, CMV). Mortality trended lower in the CMV group, but this did not reach statistical significance. The 28-d mortality in the CMV group was only 15.0%, versus 26.3% in the low-dose PLV group (p ϭ 0.06) and 19.1% in the high-dose PLV group (p ϭ 0.39). Mortality during the first 28 d after enrollment is shown in Figure 1 . Time to resolution of ARDS/ALI was significantly faster during CMV than with low-dose PLV (p Ͻ 0.001). Time to unassisted ventilation was shorter (p Ͻ 0.001), and the percentage of patients alive and off ventilation at 28 d was greater in the CMV group than in the lowdose PLV group. The results for the primary outcome variables (ventilator-free days) and secondary outcome variables (28-d mortality, time to resolution of ALI/ARDS, alive and off the ventilator at Day 28, and time to unassisted ventilation) were similar in all treatment groups for both the intention to treat (all randomized regardless of treatment) and per-protocol populations (all patients actually receiving randomized treatment). Ventilator-free days and mortality data by stratification group are presented in Table 4 . Stratification had little effect on ventilator-free days. However, both age and APACHE II score affected mortality primarily in the high-dose and CMV groups. Mortality was 7.6% for those younger than 55 yr (n ϭ 79) and 6.0% for those with an APACHE II score of less than 20 (n ϭ 67) in the CMV group. Mortality was 35.7% for all groups 55 yr and older.
Safety
Adverse events, as reported by the investigators are listed in Table 5 . There were no statistically significant differences in the incidence of bradycardias, arrhythmias, or cardiac arrests reported during the first 28 d. However, there were more reported pneumothoraces, hypoxic episodes, and hypotensive episodes in PLV patients compared with CMV patients during the first 28 d. Most of the hypoxic and hypotensive adverse events in the PLV groups occurred over the first 5 d of drug delivery and were associated with the initial and subsequent filling of the lung with PFC.
DISCUSSION
The most important findings of this study are as follows: (1 ) PLV at both low and high doses did not improve outcome compared with CMV, (2 ) a greater number of serious adverse reactions were observed with PLV than with conventional ventilation, and (3 ) the conventional ventilation strategy used in this study resulted in an improvement in ventilator-free days and a nonsignificant trend to decreased mortality.
The results of this trial are disappointing. The hypothesis of the current study was based on animal data and a post hoc analysis of a phase II trial comparing PLV with a non-PLV control group (20) . In the previous study, the PLV group had a significantly greater number of ventilator-free days and a trend toward a lower mortality rate compared with control in patients younger than 55 yr (20) . The plateau pressures in the phase II trial for all groups were 35 to 39 cm H 2 O, and in the current study they were 26 to 30 cm H 2 O in the CMV group. This difference may have contributed to the CMV mortality benefit in our trial versus the phase II trial. Outcome data for the PLV groups in this study were similar to those from the post hoc analysis of the phase II trial; however, in the present study, the control group had a much improved outcome. This study joins a large group of negative studies that were based on promising post hoc analyses (7, 25, 26) . The reason for the large number of negative post hoc trials is likely related to the statistical issue of multiple testing in which "false positives" occur by chance alone. However, it should also be understood that it is still unclear how to optimally dose PFCs and adjust ventilator settings in patients receiving PLV. Therefore, the overall role, if any, of PFCs in ventilator management of ARDS remains to be determined despite this negative study.
Why the Negative Results?
Given the putative benefits of PLV, which include decreased surface tension (9), antiinflammatory properties (12), "liquid PEEP," and redistribution of blood flow to better ventilated areas (10, 11) , and given the promising animal data (14-16), why was this trial negative? There are a number of possibilities, including the heavy sedation and paralysis required in many patients on PLV, the requirement for at least 48 h of PLV before discontinuation, the fact that PLV requires about 24 h for the PFC to evaporate, and possible repeated derecruitment of unstable lung units since patients in the PLV arm had to be disconnected from the mechanical ventilator every 3 h for either redosing or evaluation of the PFC level. However, the negative results may have been a result of the ventilatory strategy used in all groups. As we now know, a low Vt ‫ف(‬ 6 ml/kg) is ideal in ARDS (1, 2) . This study used Vts of about 9 ml/kg PBW, lower than those used in the animal studies cited above. These lower Vts may have prevented the beneficial effects of PLV from being observed. In addition, plateau pressures were higher in the PLV groups by about 3 cm H 2 O throughout the study. It may be that the benefits of adjunctive therapies demonstrated in animals ventilated with large Vts are simply overshadowed by the benefits of low ventilating pressures and Vts currently used in patients with ARDS. This combined with the unexpectedly low mortality in the control group were the primary reasons why we believe the trial results were negative. An additional reason for this negative trial may have been the population of patients studied; it may be that a different population of patients would have benefited from PLV. Finally, it may be that the high peak alveolar pressure in the most gravitydependent lung in the PLV group when applied over time enhanced injury in this group. Although plateau pressures were about 30 to 32 cm H 2 O in the PLV groups, plateau pressure does not reflect the impact of the PFCs on the dependent lung. The combined effect of pressure exerted by the PFC and the airway gas pressure may have enhanced injury over time in the PLV groups. Finally, the overall volume of fluid plus gas in the PLV groups may have markedly over distended lung, increasing susceptibility to injury.
The ARDSNet data (2) became available during the conduct of this trial. This brings up the question of whether this study should have changed to a lower Vt strategy in the control group. This is a complex issue. The current study was almost completed Definition of abbreviations: APACHE ϭ Acute Physiology and Chronic Health Evaluation; CMV ϭ conventional mechanical ventilation; PLV ϭ partial liquid ventilation; VFD ϭ ventilator-free days.
Mortality indicates 28-d mortality.
when the ARDSNet results were published. The Vts used in our study were about midway between those of the control arm and the conventional arm of the ARDSNet trial, and the mortality rates that were seen by the Data Safety Monitoring Board (albeit in a blinded fashion) were comparable to the 6-ml/kg group in the ARDSNet trial. When entry criteria differ and outcomes of the study being conducted are good, decisions are frequently made to continue the trial as designed. A good example of this is the recent prone-positioning trial by Guerin and coworkers (27) , which used a Vt of about 10 ml/kg PBW. During treatment indicates the first 5 d for the CMV groups and for as long as PLV was administered in the PLV groups; post-treatment indicates the period after treatment up to the 28th day.
* p Ͻ 0.05 versus CMV group.
High Dose versus Low Dose
Two dosing levels of PLV were tested based on efficacy data available at the time the study was initiated. Most clinical studies using PLV have used dosing to full FRC (17) (18) (19) (20) . However, nonclinical data in various lung-injury models have indicated that PLV with less than a full FRC dose may be as effective as a full FRC dose (14, 15) . Specifically, in large animals, lung compliance only improves up to a dose of 10 ml/kg (15) . Although oxygenation in animal models improves in a dose-dependent manner, the use of moderate levels of PEEP during PLV results in a similar benefit to that of large PFC dosing at low PEEP levels (28, 29) . The dosing level of approximately 20 ml/kg was chosen based on the volume of PFC used in a previous phase II trial (22 Ϯ 0.8 ml/kg) (20) and the lower dose of 10 ml/kg was based on previous studies in which this dose appeared to be effective (14, 15) .
Adverse Events
The increased numbers of hypoxic and hypotensive episodes in the PLV groups were primarily related to the interruption of ventilatory support that was required for initial dosing and subsequent dosing of PFC. In addition, the greater distending pressure in the dependent lung regions may have contributed to the higher pneumothorax rate in the PLV groups (9.3 vs. 29.4 and 28%) (10, 11) . Although all of the short-term preclinical data indicated less lung injury with PLV (30, 31) , it is easy to speculate how the long-term application of PLV might have induced this level of barotrauma.
Conventional Ventilation
Although direct comparison of mortality among different studies is fraught with uncertainty due to a number of factors, it is interesting to compare the mortality in our control group with those of other studies. The mortality rate of 15% in our control group is the lowest mortality reported in any reported randomized controlled trial of mechanical ventilation in ARDS (1, 2, 7, 25, 26, (32) (33) (34) (35) . This low mortality rate may be due to a number of factors. First, patients enrolled in our trial had fewer organ failures than many other ARDS trials and were ventilated for less than 48 h after the diagnosis of ARDS was made. In addition, the inclusion criteria only included patients younger than 65 yr; increased age is a well-known determinant of increased mortality in patients with ARDS (36, 37) . However, our patients may have had more severe lung injury at the time of enrollment based on oxygenation criteria, since we assessed oxygenation using a relatively high PEEP of 13 cm H 2 O or greater, and only patients with an Fi O 2 of 0.5 or more and a Pa O 2 /Fi O 2 less than 300 mm Hg were randomized. When the ventilation strategy used in our study is compared with that of the ARDSNet trial (2), striking differences exist. Vt in our CMV arm was about 9.0 ml/kg PBW, somewhat lower than those used in Stewart and coworkers' (32) and Brochard and colleagues' (33) studies, but greater than the 6.0 ml/kg PBW in the ARDSNet treatment arm. However, we used a PEEP level that was about 14 cm H 2 O at randomization, a value greater than that used in the three previously mentioned trials. A number of animal studies have demonstrated that higher levels of PEEP produce marked protection from ventilatorinduced lung injury. Plateau pressures in both the present study and in the ARDSNet study (2) were about 28 cm H 2 O. Given that we used a higher Vt and a higher PEEP level, this would suggest that there was marked recruitment of the lung by the application of PEEP of 13 cm H 2 O or greater from the first or second day of ARDS in our study. This leads one to speculate on the relative importance of volume, PEEP, and plateau pressure on outcome in ARDS.
Limitations
The major limitation of this study was the methodology used to check whether further dosing of PFC was required. The repetitive disconnection of the mechanical ventilator may have disadvantaged patients in the PLV groups. Only two dosing levels were used; it is possible that a much lower dose of PFC may have been more advantageous. The approach to ventilation used during PLV may not have been ideal. The use of a smaller welldefined Vt in all groups may have affected outcome. It is possible that use of high-frequency ventilation during PLV would have been more advantageous than CMV. It can be argued that this trial, similar to many other trials of innovative medical approaches, was conducted too soon. However, the results of animal studies (14-16) were positive, a phase II trial (20) identified a group of patients that might benefit from PLV, and much of the human lung protective mechanical ventilation data we know today were not available in 1998. In addition, ventilator adjustments were not guided by specific algorithms. Ranges (i.e., Vt р 10 ml/kg PBW) were defined but the clinician was free to adjust settings within the defined range as they considered clinically appropriate.
In addition, the delay between study completion and study publication must be addressed. Multiple factors clearly affect the speed of publication. Positive results are embraced by everyone and enthusiasm for publication is high. However, negative trials are not as enthusiastically embraced. The investigators' interest in pursuing the effort required to publish is diminished, and journals overall are less interested in publishing negative trials than positive trials. Despite this, it is critical that data from negative trials be available for the entire medical community to evaluate to help guide future studies. Finally, as with all studies, our results can only be generalized to others meeting our inclusion criteria including a Pa O 2 /Fi O 2 of 300 mm Hg or less at a PEEP of 13 cm H 2 O or greater and Fi O 2 of 0.5 or greater.
In conclusion, the use of PLV as applied in this study results in a greater number of serious adverse outcomes than CMV and does not improve outcome compared with CMV. PLV is not indicated in patients with severe ARDS.
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